NYSE
ABBV
Last Price
US $249.46
KEY FIGURES
MKT CAP
$440.7B
EPS
TTM
$3.57
PEG
TTM
N/M
P/E
TTM
69.90x
P/S
TTM
6.86x
YIELD
2.74%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
-136.63%
Return on equity
ROIC: 13.67%
Valuation History
69.3X
Price to Earnings
EV/EBITDA: 25.9X
Cash flow
Profit margin
5.95%
(FY vs FY)
EBITDA Y/Y
7.42%
(FY vs FY)
Cash flow Y/Y
1.19%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $249.46
-64.72%
Default assumptions
EBITDA Multiple
Fair Value
Market $249.46
-69.58%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
AbbVie Inc. cash flow to debt ratio of 27.55% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial risk - Healthy cash flow growth.
AbbVie Inc.'s free cash flow has decreased -0.09% from $17.83G last year to $17.82G, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
AbbVie Inc.'s debt to equity ratio is -11.93, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Healthy debt to equity ratio development.
AbbVie Inc.'s debt to equity ratio is -11.93, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Net debt/EBITDA.
AbbVie Inc. has a net debt to EBITDA ratio of 3.62x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk
Financial stability - ICR.
AbbVie Inc.'s interest coverage ratio of 6.73 indicates that earnings with good margin can cover interest payments on company debt
Financial stability - Profit margin growth.
AbbVie Inc.'s profit margin has increased (29.26%) in the last year from 7.59% to 9.82%, signaling increasing performance
Financial risk - Short term assets vs short term liabilities.
AbbVie Inc.'s short-term liabilities of $43.29G exceed its short-term assets of $29.06G, signaling financial risk
Decreasing performance - ROA.
AbbVie Inc.'s return on assets of 4.68% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
AbbVie Inc.'s return on equity of -136.63%, is lower than 15.00%, indicating bad performance
Increasing performance - Earnings quality.
AbbVie Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
AbbVie Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
AbbVie Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
AbbVie Inc. has a free cash flow yield of 4.04%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
AbbVie Inc.'s yearly earnings has decreased -1.22% since last year from $4.28G to $4.23G, signaling decreasing performance
Increasing performance - Healthy revenue growth.
AbbVie Inc.'s yearly revenue has increased 8.57% since last year from $56.33G to $61.16G, signaling increasing performance
Increasing performance - ROIC.
ROIC 13.67% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing performance - 3-year revenue CAGR.
AbbVie Inc.'s 3-year revenue CAGR of 1.75% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
AbbVie Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
AbbVie Inc. had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
AbbVie Inc. is overvalued relative to its fair value price of 88.01 based on Discounted Cash Flow model
Overvalued - Earnings yield.
AbbVie Inc. has an earnings yield of 1.43%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
Overvalued - EBITDA valuation.
AbbVie Inc. is overvalued relative to its fair value price of 75.89 based on EBITDA multiple model
Overvalued - EV/EBITDA.
AbbVie Inc. has an EV/EBITDA ratio of 28.62x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Overvalued - PEG ratio value.
AbbVie Inc. has a PEG-ratio over 1 which is considered overvalued
Overvalued - P/B ratio.
AbbVie Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails
Undervalued - P/S ratio.
AbbVie Inc. has a price-to-sales ratio of 6.86x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue